University of Miami Miller School of Medicine
Neurology
James E. Galvin, M.D., M.P.H. is Professor of Neurology and Psychiatry & Behavioral Sciences at the University of Miami Miller School of Medicine. He is Founding Director of the Comprehensive Center for Brain Health, Director and Principal Investigator of the Lewy Body Dementia Research Center of Excellence, and Chief of Cognitive Neurology for Palm Beach and Broward County leading brain health and neurodegenerative disease research and clinical programs. Dr. Galvin has authored over 280 scientific publications, 25 book chapters, and 3 textbooks on healthy brain aging, cognitive health, Alzheimer’s disease, Lewy Body dementia, and related disorders. Dr. Galvin’s research has been funded by the National Institutes of Health, Alzheimer’s Association, Michael J Fox Foundation, Missouri, New York, and Florida Departments of Health, and numerous Private and Family Foundations.

Presenter of 2 Presentations

Discussants

Session Type
FORUM
Date
Sun, 20.03.2022
Session Time
12:40 PM - 01:40 PM
Room
ONSITE PLENARY: 115-117
Lecture Time
12:40 PM - 01:40 PM

PRE-RECORDED: THE HEALTHY BRAIN INITIATIVE: EXAMINATION OF RESILIENCE AND VULNERABILITY FACTORS TO DISTINGUISH HEALTHY BRAIN AGING FROM NEURODEGENERATIVE DISEASE

Session Type
SYMPOSIUM
Date
Sun, 20.03.2022
Session Time
11:35 AM - 01:35 PM
Room
ONSITE: 112
Lecture Time
01:20 PM - 01:35 PM

Abstract

Abstract Body

AIMS: There is increasing interest in primary, secondary, and tertiary prevention approaches to address mild cognitive impairment (MCI) and Alzheimer’s disease and related dementias (ADRD). A significant challenge is measurement of resilience and vulnerability factors that can (a) distinguish between healthy brain aging and MCI/ADRD, and (b) serve as intervention targets. To address this challenge, we created the Resilience Index (RI), a quantifiable measure of brain health, and the Vulnerability Index (VI), a weighted measure of MCI/ADRD risk.

METHODS: We analyzed 241 participants completing a comprehensive clinical-cognitive evaluation. Six lifestyle factors (physical activity, cognitive activity, social engagement, dietary patterns, mindfulness, cognitive reserve) were combined to derive the RI. Twelve easily-obtained sociodemographic, medical, and functional factors were used to develop the VI.

RESULTS: The RI had a 9-fold odds ratio to discriminate individuals with and without cognitive impairment. Individuals with high RI scores (>143) had better cognitive, functional, and behavioral ratings than individuals with low RI scores. The VI had a 17-fold odd ratio to discriminate individuals with and without cognitive impairment. Individuals with high VI scores (≥8) had worse cognitive, functional, and behavioral ratings than those with low VI scores. Combining RI and VI scores differentiated between healthy controls and MCI/ADRD and provided insight into risk of transition/conversion.

CONCLUSIONS: The RI and VI are brief yet powerful indices of brain health and risk of MCI/ADRD. Combining resilience and vulnerability could provide a guide to develop personalized prevention plans to support brain health and identifying asymptomatic individuals for risk of MCI/ADRD.

Hide